Plant Compound Amentoflavone Blocks Muscle-Wasting Protein to Reverse Atrophy
A Ginkgo biloba biflavonoid shows strong binding to myostatin, the key brake on muscle growth, reversing atrophy in cells and mice.
Summary
Amentoflavone (AMF), a natural compound from Ginkgo biloba, was tested as a potential treatment for muscle atrophy by targeting myostatin (MSTN), a protein that suppresses muscle growth. Using computational modeling, cell culture experiments, and a mouse model of steroid-induced muscle wasting, researchers found that AMF binds stably to MSTN, inhibits its downstream signaling cascade, and promotes muscle fiber development. In atrophic mice, AMF preserved muscle mass, improved fiber size, and enhanced strength and endurance. It also suppressed muscle-degradation proteins Atrogin-1 and MuRF1 while activating the anabolic AKT/mTOR pathway. These findings position AMF as a promising natural candidate for treating sarcopenia and other muscle-wasting conditions.
Detailed Summary
Muscle atrophy, whether from aging, immobility, or corticosteroid use, represents a major health burden with limited pharmaceutical solutions. Myostatin is a well-validated negative regulator of muscle mass, making it an attractive therapeutic target. This study investigates whether amentoflavone (AMF), a biflavonoid found in Ginkgo biloba, can inhibit myostatin and counteract muscle wasting.
Researchers first used molecular docking and 100-nanosecond molecular dynamics simulations to show that AMF binds tightly and stably to the myostatin protein. A cellular thermal shift assay provided experimental confirmation of this interaction in living cells, adding credibility beyond purely computational predictions.
In cell culture, AMF enhanced differentiation of both mouse C2C12 myoblasts and human muscle satellite cells, increasing expression of key myogenic markers MYH and MYOG while reducing myostatin and phosphorylated SMAD levels — the downstream signaling molecules through which myostatin suppresses muscle growth. In dexamethasone-induced atrophic cells, AMF restored these myogenic markers and suppressed the atrophy program.
In vivo, mice with dexamethasone-induced muscle atrophy treated with AMF showed preserved body weight and muscle mass, larger muscle fiber cross-sectional areas, and measurable improvements in grip strength and endurance. Molecular analysis confirmed reduced Atrogin-1 and MuRF1 (ubiquitin ligases responsible for muscle protein degradation) and activated AKT/mTOR anabolic signaling.
While the results are compelling across multiple experimental layers, the study remains preclinical. The mouse model uses pharmacological atrophy rather than age-related sarcopenia, and human clinical data are absent. Bioavailability and optimal dosing of AMF in humans have not been established. Nonetheless, AMF emerges as a scientifically grounded natural compound warranting further development for muscle-wasting conditions including sarcopenia.
Key Findings
- AMF binds stably to myostatin protein, confirmed by molecular dynamics simulation and cellular thermal shift assay.
- AMF increased MYH and MYOG expression while reducing myostatin and SMAD signaling in human and mouse muscle cells.
- In atrophic mice, AMF preserved muscle mass, fiber size, grip strength, and endurance.
- AMF suppressed muscle-degradation proteins Atrogin-1 and MuRF1 and activated the anabolic AKT/mTOR pathway.
- Effects were validated across in silico, in vitro, and in vivo models, strengthening mechanistic confidence.
Methodology
The study used a three-tier approach: molecular docking and 100-ns MD simulations for target binding, C2C12 and human muscle satellite cell cultures for in vitro validation, and a dexamethasone-induced mouse atrophy model for in vivo efficacy. Cellular thermal shift assay provided experimental confirmation of AMF-myostatin binding.
Study Limitations
The in vivo model relies on dexamethasone-induced atrophy, which may not fully replicate age-related sarcopenia pathophysiology. No human clinical data exist, and AMF bioavailability, optimal dosing, and long-term safety in humans remain uncharacterized. The abstract does not report specific quantitative effect sizes for all outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: